The latest announcement is out from Heartseed, Inc. ( (JP:219A) ).
Heartseed Inc. has successfully completed the patient enrollment phase for its LAPiS Study, a Phase 1/2 clinical trial in Japan investigating the effectiveness of HS-001, a therapy derived from induced pluripotent stem cells, for advanced heart failure. The successful enrollment of 10 patients, split between low and high-dose arms, marks a significant milestone for the company as it continues to collect data on the therapy’s efficacy and safety, promising to expand treatment options and improve patient quality of life.
More about Heartseed, Inc.
Heartseed Inc. is a biotechnology company focusing on developing innovative stem cell-derived therapies. Their primary product, HS-001, is an investigational stem cell-derived therapy aimed at treating advanced heart failure caused by ischaemic heart disease.
YTD Price Performance: -36.96%
Average Trading Volume: 990,881
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen40.18B
See more data about 219A stock on TipRanks’ Stock Analysis page.